Press Release
Press Release
Nov 20, 2020
Teckro Expands Product Portfolio to Unblock Clinical Research Site Staff
The extension of the digital engagement platform is part of the company’s mission to ease pressure on busy staff at research sites Clinical trial software provider Teckro introduces Teckro Connect as the newest application in its digital engagement platform, giving research site staff direct and immediate access to study experts. Research staff are blocked without timely answers to questions and clarifications during the conduct of clinical trials. And they can lack confidence in the answers to complex medical questions if they are not directly from expert sources.   The communication challenges facing research site staff surfaced in recent research published by the Tufts Center for the Study of Drug Development and Teckro. For example, while study monitors are a main source of protocol information, responses back to site staff take some time. The research also highlights that medical monitors and study teams are rarely resources for research staff.      Connecting Research Sites and Study Experts Time delays and a lack of trust in the information provided cause unnecessary frustration for research site staff. Teckro addresses this frustration through a combination of mobile self-service access to all study documents with Teckro Search and a secure, dedicated communication channel for research staff to directly query study experts with Teckro Connect. With Teckro Connect, research staff can ask for clarification or confirm information from the secure Teckro mobile application. The message is received by a dedicated group of medical and scientific experts, giving everyone involved transparency into the response. This leaves no question unanswered and gives staff confidence in the fidelity of the information. It also provides a thread of communication for further clarification, if necessary. For the first time, sponsors have real-time visibility into site queries and can directly connect study experts in a controlled way with staff conducting the trials. Teckro Connect is compliant with industry regulations, including 21 CFR Part 11. All communication threads are managed to resolution and can be exported for inclusion in the trial master file.   View this infographic for more explanation about Teckro Connect and how it helps research staff get study answers they need.  Brendan Buckley, Chief Medical Officer at Teckro, says, “We understand and have empathy for how difficult it can be for site staff to conduct clinical trials. We built Teckro because accessing the protocol using old-fashioned methods is inconvenient, inefficient and time-consuming. For this reason, site staff around the world ask for Teckro on their trials.” Gary Hughes, CEO at Teckro, says, “I am proud of the work we have done to launch Teckro Connect, starting with research to deeply understand the problem.  We’re always working on new ideas to make clinical trials stakeholders’ jobs as easy as possible. This is more important than ever, and there is urgent need for simple technology solutions to reform the clinical trials process for better outcomes for staff, sponsors and patients.” About Teckro Teckro clinical trial software connects all study stakeholders with a digital engagement platform. Global pharmaceuticals and emerging biotechnology companies alike rely on Teckro for all trial phases and therapeutic areas. Teckro is used at more than 18,000 active research sites around the world. Headquartered in Limerick, Ireland, Teckro has locations across Europe and the United States. For further information, contact Hannah Lippitt +44 7393334501 or hannah@talkhealthtech.com.
Press Release
Jul 21, 2020
New Industry Research Finds that Investigative Sites Use Unsophisticated Approaches to Access Protocol Instructions, Despite Availability of Newer Technologies
Clinical trials are largely guided by static versions with staff referring to paper protocols or PDF files on desktop computers New industry research finds that investigative site staff most often rely on paper and desktop computers to reference protocol instructions. The research, conducted by the Tufts Center for the Study of Drug Development (CSDD) in collaboration with Teckro, gathered responses from 228 investigative site staff on how and when they interact with the clinical trial protocol. The findings are published in a new report: Tufts CSDD - Teckro 2020 Study on Investigative Site Protocol Administration Referencing Practices. Unsophisticated approaches gathering static information One of the major findings was that the majority of respondents (87%) “very” or “somewhat often” refer to paper versions of the protocol. A high percentage (80%) of investigative sites also report relying on direct communication with the study monitor or clinical teams for protocol instructions as well as static PDF versions of the protocol via desktop computers (79%). Unsurprisingly, smartphones and tablets are rarely used to access online versions of the protocol as navigating PDFs on smaller devices can be difficult. Only four in 10 refer to frequently asked questions via an online portal. The majority (80%) of respondents report email communication as the primary way they receive protocol amendments. Access to updates via online portals is used by only a small percentage of sites (13%). “The study results indicate that the majority of investigative sites are using unsophisticated approaches when referring to the protocol to guide clinical trial administration. This is not surprising given the high proportion of sites that are inexperienced, with minimal infrastructure, and — in many cases — involved in clinical trials as a supplemental activity to their clinical practice,” says Ken Getz, Deputy Director of the Tufts CSDD. “As clinical trial activity becomes more virtual and remote, facilitated in part by the pandemic, we expect to see investigative sites using more mobile, flexible technology solutions offering dynamic data updated in real time.” Separation between the protocol and patient The results also show that the protocol is typically accessed in a distinct area removed from where the patient is seen. Only 7% of respondents store the protocol in the clinic area. Yet, the most referred to sections of the protocol are inclusion/exclusion criteria (97%) and schedule of visits (99%). With a high percentage of sites turning to study monitors for answers regarding protocol administration, this approach is the most time intensive. Nearly six out of ten respondents (58%) report that it takes more than 20 minutes to get an answer. Study design complexity presents challenges for staff looking for answers Respondents reveal that the least accessed protocol sections are management of toxicity, data reporting requirements, and managing or reporting adverse events. In fact, 42% of respondents rarely or never access the protocol for toxicity management. Such events are typically guided by both study specific and industry standard guidelines that could result in conflicting information in the protocol, which may help to explain why site staff do not directly refer to the protocol in such instances. “What started with a question turned into a collaborative research project between Teckro and Tufts CSDD. The results point to ways we need to make it easier for research staff to conduct clinical trials,” says Brendan Buckley, Teckro Chief Medical Officer. “It’s usual for people to do an online search or to ask Siri or Alexa when they have a question. Within an instant, they get access to hundreds, thousands or even millions of answers. Why isn’t it the same with clinical trials?” For More Information The full report Tufts CSDD - Teckro 2020 Study on Investigative Site Protocol Administration Referencing Practices is available from the Resources Center. A companion analysis from Teckro entitled The Digital Paradox: Research Sites and the Clinical Trial Protocol and an infographic of the research are also available in the Resources Center. About Teckro Teckro clinical trial software connects all study stakeholders with a digital engagement platform. Global pharmaceuticals and emerging biotechnology companies alike rely on Teckro for all trial phases and therapeutic areas. Teckro is used at more than 14,000 active research sites around the world. Headquartered in Limerick, Ireland, Teckro has locations across Europe and the United States and employs more than 120 staff. For all media queries contact Hannah Lippitt, at hannah@talkhealthtech.com. Phone: +447393334501
Press Release
Jul 21, 2020
Teckro Looks to Future on 5th Anniversary: Expands Leadership Team to Accelerate Growth
Software veteran Amanda Buckley joins as Chief Operating Officer Teckro celebrates its fifth anniversary as the company expands its executive team to support growing demand due to COVID-19. The revolutionary Teckro digital engagement platform supports a number of high profile COVID-19 clinical trials for major pharmaceutical companies. Teckro is now looking to expand its global profile and take the company to the next level of growth. “Five years is an important milestone that illustrates the staying power of our vision,” says CEO Gary Hughes. “I am proud of our team and their dedication to making Teckro technology synonymous with clinical trials. As we look forward, it is important that we bring in the right people who can help accelerate our growth. This is why I am delighted to announce Amanda Buckley as the newest member of our executive team.”   Amanda brings more than 25 years of software experience, including as general manager of Veeva Systems in Europe where she was responsible for all field operations and strategy in the region. In her role as Teckro COO, Amanda will work with Gary and the senior leadership team to scale world-class operations. Amanda says: “I’m delighted to be part of the Teckro team at such an interesting time for clinical trials. As the industry responds to the wake-up call delivered by the pandemic, it is a great opportunity for solutions like Teckro to improve efficiency and reduce friction in clinical trials.”
Press Release
Nov 25, 2019
Teckro Adds New Products Following Sky-High User Adoption
Meet Teckro: the machine-learning platform revolutionizing the way clinical trials are run. High-growth clinical trials platform Teckro added two new software products in its mission to transform the industry’s efficiency and make trials more transparent for doctors, researchers and patients. The company uses machine-learning technology to transform clinical trial protocols from static documents into actionable data for research staff, monitors and sponsors. Intuitive and simple, 91% of registered users are active on the platform. Now researchers responsible for testing new medical treatments on patients around the world can receive up-to-date study information and provide feedback to improve performance with the addition of Teckro Engage and Teckro Survey. The new functionality will build on the Teckro Search product to accelerate the speed and precision by which clinical research stakeholders can locate and distribute the right information found in current, approved documents, as well as monitor engagement and trial conduct. Teckro CEO and Co-founder Gary Hughes said: “Teckro brings simplicity to the complexity of clinical trials. The high adoption and extremely positive user feedback are unheard of for typical software companies. We are adding to the value of Teckro with the new products, which we designed to be intuitive and easy to use.” With more than 12,000 research sites using the platform - and steadily rising - Teckro holds a vast amount of valuable insight across clinical studies around the world. That volume of data will help transform what has - until now - been a painstakingly slow clinical research process, into one that is effective for every stakeholder. Dana Anderson, CCRC at North Georgia Clinical Research has been responsible for coordinating clinical trials for 18 years. She is using Teckro for a current global clinical trial and said it is making it easier to do her job as a site coordinator. “A research project involves so many stakeholders and so much paperwork. Most of the time it’s very difficult to find exactly what you’re looking for,” Anderson said. “Once I downloaded Teckro to my phone, I realized this is going to make my job much easier. It's very easy to navigate and find what information you need to retrieve from the protocol or the study design. Teckro gives us the resources that we need to make sure our data is clean and accurate. And it's nice that Teckro always will have the current amendment on there, so you know that you're following the correct protocol.” In detail, Teckro’s new products are: Teckro Engage gives study administrators a consistent way to communicate important changes, new document versions, or helpful tips to limit protocol deviation. Open rates show message effectiveness. Teckro Survey is a web-based tool for study teams to quickly design and send short surveys, making it practical to gather feedback from research staff to manage risk and improve study design. Teckro products are built on the Teckro Platform. Available through a secure mobile application or a website, Teckro doesn’t require any software installation. As a result, Teckro is operational in a matter of a couple of weeks and requires minimal user training. Business impact to date is impressive. Teckro’s own data shows that sites using Teckro screen and randomize significantly more patients compared with those without Teckro. Those sites actively searching in Teckro perform much better to meet recruitment timelines, addressing a major barrier to conducting clinical trials. About Teckro Teckro clinical trial software transforms the study protocol into actionable data for everyone – research staff, CROs and sponsors. Global pharmaceuticals and emerging biotechs alike digitize their clinical trials with Teckro. Headquartered in Ireland, Teckro has locations across Europe and the United States. Visit www.teckro.com for more information.
Press Release
Jul 18, 2019
Teckro Announces 45 High Tech Jobs in Dublin
Main expansion is in Dublin-based Engineering Excellence Hub as Teckro heavily invests in product development to simplify and modernize clinical research  Teckro, the indigenous Irish firm transforming clinical trials for leading pharmaceutical and emerging biotech companies today officially announced 45 high-end tech jobs for Dublin, representing more than 100% growth in staff here. The company currently has more than 110 employees with offices in Limerick and the US, but the majority of the new roles will be in the company’s Engineering Excellence Hub in Dublin’s Silicon Docks. The technical jobs will span functions across engineering, data science, design and usability, quality and product management. The staff expansion follows the recent appointments of Anita Callan as Vice President of Product, most recently from Aer Lingus, and Neil Flanagan as Vice President of Engineering, previously with Munich Re to Teckro’s leadership team. Speaking at the announcement CEO and Co-Founder Gary Hughes said, “Although technology has revolutionized so many industries, the experience of participating in a clinical trial if you are a doctor, research nurse or patient has not changed in the last two decades. The industry still heavily relies on paper and inefficient processes. At Teckro, we are on a mission to simplify the process and make clinical trials more accessible for everyone involved. We are looking for more talented people, especially in technical roles, to join us and make an impact.”  The company, founded in 2015 by brothers Gary and Nigel Hughes and CTO Jacek Skrzypiec, is currently in scale out mode. This is the second startup founded in Ireland by the Hughes brothers and Skrzypiec, whose previous business, Firecrest Clinical, was sold to Nasdaq-listed clinical research giant ICON in 2011. Teckro provides solutions to simplify and modernize clinical research for leading pharmaceutical and biotech companies, currently managing more than 100 clinical trials and actively used by more than 11,800 study sites worldwide. Earlier this year the company announced a Series C funding round from major US venture capital firms, including Founders Fund, Bill Maris’ Section 32, Borealis Ventures, Northpond Ventures and Sands Capital Ventures that brought its total funding to $43 million and making it one of the fastest growing venture-backed companies developing product in Ireland. Minister for Business, Enterprise and Innovation Heather Humphreys welcomed the jobs saying, “It’s great to see an Irish company based in Dublin and Limerick succeed and grow internationally, especially one with a mission that will ultimately benefit patients and healthcare professionals in research to address global health problems. These 45 new tech jobs will play an important role for Teckro to deliver solutions from Ireland that will improve the clinical trial process throughout the world. This is another great example of how our SMEs are investing in new technologies, which is an important element in our Future Jobs Ireland strategy.” About Teckro Teckro clinical trial software transforms the study protocol into actionable data for everyone – research staff, CROs and sponsors. Global pharmaceuticals and emerging biotechs alike digitize their clinical trials with Teckro. Headquartered in Ireland, Teckro has locations across Europe and the United States. Visit www.teckro.com for more information.
Press Release
Jul 02, 2019
Teckro Expands Leadership Team
Founders Fund-backed company announces hires with domain experience from publicly traded companies including Veeva Systems, Salesforce, and ICON Teckro, the company transforming clinical trials for the world’s leading pharmaceutical and emerging biotech firms, today announced five significant appointments to its leadership team as it executes aggressive go-to-market and product strategies. The hires follow Teckro’s Series C funding announcement in February, featuring investment from major US venture capital firms, including Founders Fund, Bill Maris’ Section 32, Borealis Ventures, Northpond Ventures and Sands Capital Ventures. To date, Teckro has raised $43 million, with the latest round of $25 million earmarked for scale-up activities to accelerate growth and meet a sharp increase in demand from pharmaceutical and biotech companies looking to simplify and modernize clinical trials with Teckro. Speaking on the appointments to the leadership team, Teckro CEO and co-founder Gary Hughes said, “Every clinical trial starts with a question. At Teckro, we believe that finding answers should be simple for all study stakeholders anytime, anywhere. The new leadership appointments are important as we continue to expand our product and commercial strategies. I am delighted to have this group of seasoned professionals from established public companies join Teckro on our mission to simplify and modernize clinical research.” Teckro’s new hires bring vast experience across domains, including medical affairs, commercial and engineering: Professor Brendan Buckley, Chief Medical Officer With more than four decades in academic clinical practice, Buckley brings extensive experience as a senior clinical investigator. Buckley has served in several independent regulatory roles in the European Medicines Agency (EMA) and the Irish competent authority. With more than 150 scientific papers published, Buckley also authored the recent opinion-leading book Re-Engineering Clinical Trials. From 2011-2017, Buckley served as Chief Medical Officer and Executive Vice President of ICON, one of the world’s largest clinical research organizations. Kelly Brown, Chief Marketing Officer and Sandra Blaser, VP of Services & Success Also joining Teckro from global life science software giant Veeva Systems are Kelly Brown and Sandra Blaser as Chief Marketing Officer and Vice President of Services & Success, respectively. Brown, previously VP of Marketing in Europe at Veeva, brings more than a decade of experience in the technology sector, including an 11-year stint at EMC (now Dell EMC). Early in her career, Blaser was one of first European employees at Salesforce and served as its first-ever customer success manager in the region. Before joining Teckro, Blaser spent more than five years at Veeva where she managed the customer success team in Europe. Anita Callan, VP of Product and Neil Flanagan, VP of Engineering On the technical side, Teckro bolsters its team with two seasoned professionals, Anita Callan and Neil Flanagan, who collectively will use their vast experience to ensure Teckro’s products meet and exceed customer expectations. Callan joins as Vice President of Product, most recently working at Aer Lingus where she held product and content strategy positions. Flanagan joins as Teckro Vice President of Engineering with extensive experience in building and running highly scalable technology teams. Prior to Teckro, Flanagan most recently was Head of Digital Operations at Munich Re, one of the world’s largest reinsurance companies. Collectively, these new leaders are instrumental in Teckro’s mission to simplify and modernize clinical research. Demand is strong as the number of trials on Teckro has more than tripled over the past couple of years. Today, more than active 11,800 study sites use Teckro in all major countries around the world. Equally important, user adoption of Teckro is high, with more than 90% of registered users active on the platform. About Teckro Teckro clinical trial software transforms the study protocol into actionable data for everyone – research staff, CROs and sponsors. Global pharmaceuticals and emerging biotechs alike digitize their clinical trials with Teckro. Headquartered in Ireland, Teckro has locations across Europe and the United States. Visit www.teckro.com for more information.
Press Release
Feb 14, 2019
Teckro Raises $25 Million Series C Round to Speed up Clinical Trials
Teckro’s total funding rises to $43 million to date from the likes of Northpond Ventures, Founders Fund and Bill Maris’ Section 32  Teckro has raised a fresh round of funding to accelerate its international expansion and product development. The $25 million Series C round was led by Northpond Ventures with participation from Founders Fund, Sands Capital Ventures, Bill Maris’ Section 32 venture fund, and Borealis Ventures. Teckro’s total funding now stands at $43 million. The company provides technology to improve the speed and accuracy of clinical trials, working with the top pharmaceutical and biotech companies globally. Teckro has grown rapidly since it was founded by brothers Gary and Nigel Hughes and Jacek Skrzypiec in 2015. The founders sold their previous company, Firecrest, to global clinical research giant ICON plc in 2011. Teckro is used in clinical research sites around the world in all major countries. There has been a 240% increase in the number of clinical trials on the Teckro platform over the past 12 months. The company employs more than 100 staff across its three global bases, including its global headquarters in Limerick, Ireland, its engineering hub in Dublin, Ireland and its US office in Nashville, Tennessee.  Speaking on the funding announcement, CEO and co-founder Gary Hughes said the company will use the Series C round to further the company’s mission to deliver solutions that deliver meaningfully impact and improve processes for all stakeholders involved in clinical trials. “Despite all the talk of digital transformation, the actual experience of participating in a clinical trial if you are a doctor, research nurse or patient has changed little in the last 20 years. The industry still relies heavily on paper, on working off retrospective data, and there is still an over-reliance on sending CRAs to busy research sites. This approach, together with the plethora of point solutions that get ‘bolted on’, only adds to the complexity and disjointed experience of research sites and patients. Our vision is to be at the center of all site and patient interactions in a clinical trial. We are building a new digital infrastructure and toolset for clinical research that makes the conduct of trials simpler, more transparent and more inclusive. Ultimately Teckro is about ensuring that effective drugs are efficiently and effectively moved from the lab to the patient so that lives be saved.” Michael Rubin, M.D., Ph.D., Founder & CEO of Northpond Ventures commented: “Teckro is building a digital infrastructure that can transform how clinical trials are conducted. We are excited by the team and what they have achieved to date and look forward to supporting them on this important mission.” About Teckro Teckro clinical trial software transforms the study protocol into actionable data for everyone – research staff, CROs and sponsors. Global pharmaceuticals and emerging biotechs alike digitize their clinical trials with Teckro. Headquartered in Ireland, Teckro has locations across Europe and the United States. Visit www.teckro.com for more information.
Press Release
Aug 31, 2017
Teckro Raises $10 Million in Series B Funding
Financing to accelerate momentum with world’s leading pharmaceutical and biotech companies Teckro announced the completion of its $10 million Series B financing as they expand the digitization of clinical trials. The round was led by Sands Capital Ventures with participation from Bill Maris’ Section 32 venture fund, Founders Fund and private investors. The company has raised $17.8 million to date, and its digital platform is already driving increased speed and accuracy of clinical trials at thousands of research sites in more than 30 countries.  “Teckro’s plans are ambitious and they come with a real passion for improving clinical research,” said Gary Hughes, Teckro CEO. “This investment reflects that ambition as we expand operations and customer footprint globally, continue to invest in our product platform, and drive success for our customers at the top 10 pharmaceutical and biotech companies.”  Teckro uses information retrieval and machine learning technologies to improve the speed and accuracy of clinical trial conduct, helping turn research and development into successful drugs and treatment for the world’s most complex diseases. The Teckro digital platform is deployed across multiple phases of clinical trials, including critical Phase III studies.  Teckro was co-founded by Gary Hughes, Jacek Skrzypiec and Nigel Hughes, a trio of entrepreneurs with demonstrated success and sizable exits. They previously co-founded Firecrest Clinical, acquired by global clinical research organization ICON Plc in 2011. The company is chaired by Peter Gray, Chairman of UDG Healthcare Plc, board member of Jazz Pharmaceuticals Plc, and former CEO of ICON.  Michael Rubin, Managing Partner of Sands Capital Ventures commented: “Teckro is delivering on its vision to transform clinical trials for the benefit of all stakeholders – sponsors, clinicians and patients - which is what makes this investment opportunity so compelling. Teckro’s team has unparalleled experience in the clinical trials space, and as market leaders they are solving some of the industry’s biggest challenges and winning praise from key customers.”  Bill Maris, founder of Section 32, a recently launched venture fund focused on frontier technology, founder and former CEO of GV (formerly Google Ventures), and creator of Google's Calico project, a multi-billon dollar company focused on the genetic basis of aging, added: “The Teckro platform simplifies digital trials, enabling more and more physicians to become clinical researchers and that could lead to great news for patients.”  About Teckro  Teckro partners with leading pharmaceutical/biotech companies and research institutions to simplify the clinical development process – a recognized bottleneck in the effort to bring new, safe and effective drugs to market.   About Sands Capital Ventures Sands Capital Ventures, a venture capital firm in the Washington D.C. area, partners with transformative and innovative businesses in a concentrated fashion with specific focus on technology, life sciences, and global consumer industries.  About Section 32 Section 32 is a recently launched venture fund focused on frontier technology founded by Bill Maris. Bill is the founder and former CEO of GV (formerly Google Ventures). About Founders Fund Founders Fund invests in science and technology companies solving the world’s most difficult problems. The firm and its partners have been early backers of some of the most prominent companies of the past decade, including SpaceX, Palantir, Facebook and Airbnb. Founders Fund pursues a founder-friendly investment strategy that provides maximum support with minimum interference.
Press Release
Aug 08, 2016
Teckro Completes $6 Million Series A Funding
Financing round led by Founders Fund Teckro, a life sciences technology company, has raised $6 million in Series A funding to support further development and expansion of its mobile software platform for clinical trials. The investment was led by San Francisco-based Founders Fund with participation from Enterprise Ireland and private investors. This brings the total amount of funding raised to date to $7.8 million. Teckro uses information retrieval and machine learning technologies to improve the speed and accuracy of trial conduct. The technology has already been adopted by a number of leading pharmaceutical companies. CEO Gary Hughes commented: “We set out to make a difference, to make it easier for drug developers, research staff and patients to connect, and to simplify every interaction in the conduct of a clinical trial. The funding will be used to expand our product development team as we continue to digitize clinical research services.” Hughes added: “Fundamentally, the clinical trial landscape has changed and physicians struggle with the current method of conducting clinical trials. The funding we are announcing today validates our unique approach and the growth potential of the company.” Teckro was co-founded by Gary Hughes, Jacek Skryzpiec and Nigel Hughes. They were previously co-founders of Firecrest Clinical, which was acquired by ICON Plc in 2011. Teckro is chaired by Peter Gray, former CEO of ICON, who is also Chairman of UDG Healthcare plc and a director of Jazz Pharmaceuticals plc and Aptuit LLC. Scott Nolan, Partner at Founders Fund, commented: “We’re really impressed by the Teckro team and their vision for clinical research. There’s a clear opportunity in modernizing how clinical trials are run, and Teckro’s mobile-first solution is informed by a first hand understanding of the challenges involved in conducting global clinical trials.” About Teckro Teckro partners with leading pharmaceutical/biotech companies and research institutions to simplify the clinical development process – a recognized bottleneck in the effort to bring new, safe and effective drugs to market. The company was founded in June 2015 and is headquartered in Limerick, Ireland. About Founders Fund Founders Fund invests in science and technology companies solving the world’s most difficult problems. The firm and its partners have been early backers of some of the most prominent companies of the past decade, including SpaceX, Palantir, Facebook and Airbnb. Founders Fund pursues a founder-friendly investment strategy that provides maximum support with minimum interference.